Methamphetamine Use Disorder
Conditions
Keywords
methamphetamine, treatment, behavioral intervention
Brief summary
Reduced drug use is a clinically meaningful target for treatment development, but few studies have evaluated the positive impacts produced by this behavioral change, preventing adoption of this endpoint in clinical trials. The proposed research will fill that critical knowledge gap by demonstrating the biopsychosocial benefits of reduced methamphetamine use. These data will be used to change current accepted methamphetamine treatment endpoints and accelerate identification of therapies for methamphetamine use disorder.
Interventions
BEHAVIORALContingency Management
Subjects will receive payments for providing methamphetamine negative urine samples.
Sponsors
William Stoops
National Institute on Drug Abuse (NIDA)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* be age 18 years or older; * self-report methamphetamine use in the week prior to screening; * provide a methamphetamine-positive urine sample at screening; * meet DSM-5 criteria for moderate-severe Methamphetamine Use Disorder (MUD); * be seeking treatment for their methamphetamine use * be able and willing to commit to the 12-week intervention, as well as the 12-week post-intervention follow-up * Individuals who meet these criteria and are stably maintained on buprenorphine or methadone for Opioid Use Disorder (OUD) will also be eligible to participate.
Exclusion criteria
* current or past medical or psychiatric illness (e.g., physical dependence on any drug other than buprenorphine requiring medically managed detoxification, unstable angina, uncontrolled cardiac arrhythmia, aortic stenosis, self-reported compromised immune function, severe diagnosis for a SUD other than MUD or treated OUD) that would interfere with study participation in the opinion of the study physicians * poor venous access precluding blood draws
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Arterial Pressure | At baseline. | Mean Arterial Pressure is recorded during subject visits and is recorded in mm Hg |
| Endothelin-1 | At baseline. | Endothelin-1 levels will be measured. They will be recorded in pg/ml. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Sleep | At baseline. | Sleep will be measured with the Pittsburgh Sleep Quality Index, with a range from 0-21 where lower scores are better. |
Countries
United States
Contacts
CONTACTWilliam W Stoops, PhD
PRINCIPAL_INVESTIGATORWilliam W Stoops, PhD
University of Kentucky
Outcome results
None listed